Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of Advanced Prostate Cancer.

Literature DB >> 30228709

Treatment of Advanced Prostate Cancer.

Theodore S Thomas¹, Russell K Pachynski².

Abstract

Advanced prostate cancer is a heterogenous disease with multiple treatment options. Patients with advanced disease are stratified based evidence of metastasis and sensitivity to hormone therapy. Men with hormone sensitive disease are treated with androgen deprivation therapy and possibly chemotherapy. The treatment options for men with castrate resistant disease are rapidly evolving with multiple recently approved treatment options. Determining the proper sequence and combination of these therapies remains a work in progress.

Entities: Disease Species

Mesh：

Substances：

Year: 2018 PMID： 30228709 PMCID： PMC6139850

Source DB: PubMed Journal: Mo Med ISSN： 0026-6620

24 in total

1. The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy.

Authors: Luis A Kluth; Shahrokh F Shariat; Christian Kratzik; Scott Tagawa; Guru Sonpavde; Malte Rieken; Douglas S Scherr; Karl Pummer
Journal: World J Urol Date: 2013-09-03 Impact factor: 4.226

2. Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors: Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal: N Engl J Med Date: 2012-08-15 Impact factor: 91.245

3. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

Authors: P W Kantoff; S Halabi; M Conaway; J Picus; J Kirshner; V Hars; D Trump; E P Winer; N J Vogelzang
Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544

4. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors: Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal: Lancet Date: 2010-10-02 Impact factor: 79.321

5. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.

Authors: Tomasz M Beer; Eugene D Kwon; Charles G Drake; Karim Fizazi; Christopher Logothetis; Gwenaelle Gravis; Vinod Ganju; Jonathan Polikoff; Fred Saad; Piotr Humanski; Josep M Piulats; Pablo Gonzalez Mella; Siobhan S Ng; Dirk Jaeger; Francis X Parnis; Fabio A Franke; Javier Puente; Roman Carvajal; Lisa Sengeløv; M Brent McHenry; Arvind Varma; Alfonsus J van den Eertwegh; Winald Gerritsen
Journal: J Clin Oncol Date: 2016-10-31 Impact factor: 44.544

6. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245

7. Intermittent versus continuous androgen deprivation in prostate cancer.

Authors: Maha Hussain; Catherine M Tangen; Donna L Berry; Celestia S Higano; E David Crawford; Glenn Liu; George Wilding; Stephen Prescott; Subramanian Kanaga Sundaram; Eric Jay Small; Nancy Ann Dawson; Bryan J Donnelly; Peter M Venner; Ulka N Vaishampayan; Paul F Schellhammer; David I Quinn; Derek Raghavan; Benjamin Ely; Carol M Moinpour; Nicholas J Vogelzang; Ian M Thompson
Journal: N Engl J Med Date: 2013-04-04 Impact factor: 91.245

Review 8. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature.

Authors: Piet Ost; Alberto Bossi; Karel Decaestecker; Gert De Meerleer; Gianluca Giannarini; R Jeffrey Karnes; Mack Roach; Alberto Briganti
Journal: Eur Urol Date: 2014-09-17 Impact factor: 20.096

9. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.

Authors: David F Penson; Andrew J Armstrong; Raoul Concepcion; Neeraj Agarwal; Carl Olsson; Lawrence Karsh; Curtis Dunshee; Fong Wang; Kenneth Wu; Andrew Krivoshik; De Phung; Celestia S Higano
Journal: J Clin Oncol Date: 2016-01-25 Impact factor: 44.544

10. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Authors: Nicholas D James; Matthew R Sydes; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Christopher C Parker; J Martin Russell; Gerhardt Attard; Johann de Bono; William Cross; Rob J Jones; George Thalmann; Claire Amos; David Matheson; Robin Millman; Mymoona Alzouebi; Sharon Beesley; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir Chakraborti; Simon Chowdhury; Audrey Cook; Tony Elliott; Joanna Gale; Stephanie Gibbs; John D Graham; John Hetherington; Robert Hughes; Robert Laing; Fiona McKinna; Duncan B McLaren; Joe M O'Sullivan; Omi Parikh; Clive Peedell; Andrew Protheroe; Angus J Robinson; Narayanan Srihari; Rajaguru Srinivasan; John Staffurth; Santhanam Sundar; Shaun Tolan; David Tsang; John Wagstaff; Mahesh K B Parmar
Journal: Lancet Date: 2015-12-21 Impact factor: 79.321

4 in total

1. Identification of potential biomarkers and pivotal biological pathways for prostate cancer using bioinformatics analysis methods.

Authors: Zihao He; Xiaolu Duan; Guohua Zeng
Journal: PeerJ Date: 2019-10-04 Impact factor: 2.984